Additional file 1 of A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model

Additional file 1. Section S1. Relationship between impact, uptake and effectiveness. Section S2. Case data. Section S3. Vaccine uptake and person-years data. Section S4. Model’s inference. Section S5. Model’s predictions. Section S6. Predictive accuracy of the incidence model. Section S7. Alternative models. Table S1. Serogroup B IMD case counts shared by PHE and used for our re-assessment. Table S2. Best estimates of the parameters. Figure S1. Person-years by age and year. Figure S2. Person-years / 100,000 by age, year and doses received. Figure S3. Case data and model predictions by age, time and doses received. Figure S4. Residuals and predicted vs. observed cases. Figure S5. Sampled parameters and their distributions.